Meta-analysis of the efficacy and safety of daratumumab in the treatment of multiple myeloma

Table 1 Basic characteristics of literature

Ref.	Year	Interventions		Number of examples		Outcome indicators
		Experimental	Control	Experimental	Control
Bahlis et al[4], POLLUX	2020	Lenalidomide + dexamethasone + Daratumumab	Lenalidomide + dexamethasone	368	369	ORR, CR, adverse reactions
Dimopoulos et al[5], CANDOR	2020	Caffezomib + Dex + Daratumumab	Caffezomib + Dex	312	154	PFS, ORR, CR, adverse reactions
Dimopoulos et al[6], APOLLO	2021	Poloxamer + dexamethasone + Daratumumab	Poloxamer + Dex	151	153	PFS, ORR, CR, adverse reactions
Facon et al[7], MAIA	2021	Lenalidomide + dexamethasone + Daratumumab	Lenalidomide + dexamethasone	368	369	PFS, ORR, CR, adverse reactions
Mateos et al[8], CASTOR	2020	Bortezomib + dexamethasone + Daratumumab	Bortezomib + dexamethasone	251	247	PFS, ORR, CR, adverse reactions
Mateos et al[9], ALCYONE	2020	Bortezomib + melphalan + prednisone + Daratumumab	Bortezomib + melphalan + prednisone	346	354	PFS, ORR, CR, adverse reactions
Moreau et al[10], CASSIOPEIA	2019	Bortezomib + thalidomide + dexamethasone + Daratumumab	Bortezomib + thalidomide + dexamethasone	543	542	PFS, ORR, CR, adverse reactions
Voorhees et al[11], GRIFFIN	2020	Lenalidomide + bortezomib + dexamethasone + Daratumumab	Lenalidomide + bortezomib + dexamethasone	99	97	ORR, CR, adverse reactions
Yan et al[12]	2021	Bortezomib + cyclophosphamide/doxorubicin + dexamethasone + Daratumumab	Bortezomib + cyclophosphamide/doxorubicin + dexamethasone	64	51	CR, adverse reactions

PFS: Progression-free survival; ORR: Overall response rate; CR: Complete remission.